Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : University of Missouri-Columbia
Deal Size : Undisclosed
Deal Type : Collaboration
AI Proteins Signs Collaborative Research Agreement on Radioligand Therapy
Details : The collaboration aims to advance the use of de novo designed miniproteins for targeted radioligand therapy, labeled with alpha and beta-emitting radionuclides are effective as a cancer theranostic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : University of Missouri-Columbia
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $400.0 million
Deal Type : Collaboration
Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M
Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $400.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration
Vivtex and AI Proteins Collaborate On Oral Biologic Therapies
Details : The collaboration aims to develop oral biologic therapies for inflammatory diseases, leveraging Vivtex’s GI-ORIS™ technology to enhance bioavailability of AI Proteins’ miniproteins.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration